Interestingly, SRCIN1 hypermethylation did not occur in other cancer types within the Taiwanese and TCGA datasets, confirming the usefulness of SRCIN1 as a biomarker specifically for breast cancer patients. This evidence concerns the gene SRCIN1 and breast carcinoma.